Background: Stent underexpansion is a strong predictor of restenosis after bare-metal stent and first-generation drug-eluting stent (Sirolimus and Paclitaxel-eluting stent) implantation. However, the implication of underexpansion in Zotarolimus-eluting stent(ZES) and Everolimus-eluting stent(EES) has not been addressed yet. Methods: Angiographic and intravascular ultrasound(IVUS) data immediately after stenting and at 9-month follow-up were available in 912 patients with 990 lesions: 541 sirolimus-eluting stent(SES), 220 ZES, 229 EES. The minimal stent area(MSA) predicts angiographic in-stent restenosis(ISR) was determined. Results: The post-procedural IVUS MSA was 6.4짹1.8 mm2, 6.2짹2.1 mm2, 6.2짹2.1 mm2 in SES, ZES, EES group. At 9-months follow-up, ISR was similar in SES, ZES and EES group. (3.3%, 4.5%, 4.4%, p=0.53) Using multivariable logistic regression analysis, the only independent predictor of ISR in each stent group was post-interventional IVUS MSA. (p<0.001 for SES, p=0.003 for ZES and p=0.015 for ZES). Using receiver operating characteristic analysis, post-interventional IVUS MSA was shown as faithful discriminator between ISR and non-ISR(c=0.739 for SES, c=0.672 for ZES and c=0.639 for EES). The optimal cut-off value of post-interventional IVUS MSA predict stent patency at 9 months were 5.5 mm2 for SES, 5.3 mm2 for ZES and 5.4 mm2 for EES. Conclusions: Post-interventional IVUS MSA is also a strong predictor of restenosis after second-generation drug-eluting stent implantation.